Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.

MLA

Fierens, Liselotte, et al. “Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.” Journal of Crohn’s & Colitis, vol. 16, no. 7, Aug. 2022, pp. 1059–69. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjac009.

APA

Fierens, L., Liefferinckx, C., Hoefkens, E., Lobatòn, T., Dreesen, E., Sabino, J., & Ferrante, M. (2022). Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies. Journal of Crohn’s & Colitis, 16(7), 1059–1069. https://doi.org/10.1093/ecco-jcc/jjac009

Chicago

Fierens, Liselotte, Claire Liefferinckx, Eveline Hoefkens, Triana Lobatòn, Erwin Dreesen, João Sabino, and Marc Ferrante. 2022. “Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.” Journal of Crohn’s & Colitis 16 (7): 1059–69. doi:10.1093/ecco-jcc/jjac009.